Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Ensysce Biosciences Inc. Speaking at 3rd Human Abuse Liability & Abuse-Deterrent Formulation Conference

Ensysce Biosciences Inc.
Posted on: 25 Oct 16

Dr. William K. Schmidt, Chief Medical Officer of Ensysce Biosciences Inc. will be a featured speaker at the 3rd Human Abuse Liability & Abuse-Deterrent Formulation Conference taking place November 2-3 in Arlington, VA. This conference is the premier annual industry event specifically devoted to improving trial designs, engineering less abuse-prone molecules and delivery systems, and tracking the performance and market uptake of opioids in order to document the success of abuse-deterrent methods. Dr. Schmidt’s talk, “Build an Oxycodone Prodrug with MPAR (Multi-Pill Abuse Resistance) Overdose Protection Technology” is scheduled to be presented on Thursday, Nov. 3. The talk will highlight the oxycodone prodrug, PF614 and other trypsin-activated BIO-MD™ prodrugs developed by Ensysce Biosciences. The Ensysce products have inherent abuse deterrence since they are pharmacologically and chemically inert until activation by pancreatic trypsin. The product pipeline includes immediate-release (IR) or extended-release (ER) analogues with timed activation created by novel chemical linkers used to create prodrugs of opioids, stimulants and other drugs that present challenges for duration of action, abuse-deterrence, solubility or oral bioavailability. Additionally, Dr. Schmidt will discuss Ensysce’s combination MPAR™ products that combine the BIO-MD™ prodrugs with trypsin inhibitors to provide overdose protection for each product. The MPAR™ technology has been demonstrated in a Phase 1 clinical study with PF329, an extended-release hydromorphone prodrug. Ensysce prodrugs will be contrasted to current and emerging prodrug technologies with other oral, parenteral and nasal abuse-deterrence technologies and will profile PF614, an extended-release oxycodone prodrug that is entering a Phase 1 clinical trial in November 2016. Other details regarding the conference are at http://exlevents.com/3rd-human-abuse-liability-abuse-deterrent-formulations.

About Ensysce Biosciences:

Ensysce Biosciences, San Diego CA, is an integrated drug delivery company for both small and large molecules, using prodrug technology and single walled carbon nanotubes (SWCNT) respectively. The BIO-MDTM prodrug abuse deterrent and MPAR™ overdose resistant pain platforms of Ensysce eliminate the ability to abuse opioid products by the non-oral route, something that is the fastest growing drug problem in the US and that leads to billions in healthcare costs annually. The technology, with worldwide intellectual patent protection, has been successfully validated in a Phase 1 study of the BIO-MDTM hydromorphone prodrug, PF329. A second clinical program for the BIO-MDTM abuse deterrent oxycodone prodrug, PF614 is being launched November 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161025005006/en/

Business Wire
www.businesswire.com

Last updated on: 25/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.